Loading stock data…
$31.73+2.37 (+8.07%)
Quince Therapeutics, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases.
Quince Therapeutics, Inc. in the Healthcare sector is trading at $31.73 with a market capitalization of $30M. Wall Street consensus targets $75.00 (8 analysts), implying a +136.4% move over the next 12 months. The stock is currently near its 52-week low of $15.10, remaining 65.4% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$22.09M↓ | -$11.11M↑ | -$16.24M↓ | -$11.36M↓ | -$9.89M |
| Net Income | -$75.49M↓ | $35.91M↑ | -$39.46M↓ | -$13.44M↑ | -$16.05M |
Quince Therapeutics, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises eDSP, which is in Phase 3, for the...